List of publicly available manuscripts:

  1. Senzer N et al:  Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer.  Molecular Therapy 2012 Mar 1; 20(3):679-686. 
  2. Senzer N et al: Long Term Follow Up: Phase I Trial of “bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell” Immunotherapy (FANG™) in Advanced Cancer. Journal of Vaccines & Vaccination 2013; 4(8):209.  
  3. Nemunaitis J et al: Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver.  Oncology 2014;87:21-29.
  4. Ghisoli M et al:  Pilot Trial of FANG Immunotherapy in Ewing’s sarcoma.  Molecular Therapy 2015 Jun;23(6):1103-9.
  5. Ghisoli M et al:  Three Year Follow up of VigilTM Immunotherapy in Metastatic Advanced Ewing’s sarcoma. Mol Ther. 2016 Aug;24(8):1478-83.
  6. Nemunaitis J et al: “This is another tool in our oncology toolbox.  Immunotherapy approaches engaged in clinical testing are highly visible..." of: [Iwasa S et al. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients. Cancer Sci 2016 May; 107(5):590-600; DOI: 10.1111/cas.12919]. Faculty of 1000, 01 Jul 2016. F1000.com/726192170.
  7. Ghisoli M et al: Review: Innovative Exploratory Clinical Approaches for Relapsed and/or Refractory Metastatic Ewing’s sarcoma. Pediatric Cancers-Clinics in Oncology 2016; 1:1079.
  8. Oh J et al: Phase II Study of Vigil® DNA Engineered Immunotherapy as Maintenance in Advanced Stage Ovarian Cancer. Gynecologic Oncology 2016; 143(3):504-510.
  9. Nemunaitis J et al:  Editorial:  Tumor Vaccines and Cellular Immunotherapies.  Annals of Translational Medicine 2016 Oct;4(Suppl 1):S24.
  10. Barve M et al:  Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in Patients with Advanced Melanoma. Biomedical Genetics and Genomics 2016; 1(3)81-86.
  11. Ghisoli M et al: Case Report: Immune Mediated Complete Response in a Patient with Recurrent Advanced Ewing’s sarcoma (EWS) Following Vigil® Immunotherapy. Journal of Pediatric Hematology/Oncology 2017;39:e183–e186
  12. Manning L, Nemunaitis J. Harnessing the immune response to target tumors. Faculty of 1000. 2017 May 18;6(F1000 Faculty Rev):710 (doi: 10.12688/f1000research.10795.1).
  13. Manning L, Nemunaitis J. Future Directions for Immunotherapy in Ovarian Cancer. J Gynecol Women’s Health. 2017; 2(3): 555587.
  14. Manning L, Barve M, Wallraven G, Kumar P, Taquet N, Bognar E, Mendeloff E, Oh J, Rao D, Pappen BO, Senzer N, Nemunaitis J. Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors. Clinics in Oncology. 2017 April 3; 2:1254.
  15. Barve M, Barve R, Rao D, Rao J, Manning L, Adams N, Senzer N, Nemunaitis J. Case Report: Vigil Therapy in Pathology Defined High-Risk Differentiated Thyroid Cancer Compounded by Post Ablation High-Risk Factors. J Surg Oncol Clin Res. 2017; 1(1): 1005.